T1	p 159 197	atherosclerosis in diabetic patients :
T2	p 279 311	Sonographic Coronary Obstruction
T3	p 550 558	coronary
T4	p 676 733	, 360 diabetic patients with coronary artery disease were
T5	p 859 891	Sonographic Coronary Obstruction
T6	p 1167 1175	patients
T7	p 2449 2468	diabetic patients .
T8	p 2559 2607	diabetic patients with coronary artery disease .
T9	i 119 131	pioglitazone
T10	i 216 225	PERISCOPE
T11	i 228 240	Pioglitazone
T12	i 451 463	pioglitazone
T13	i 628 639	glimepiride
T14	i 747 774	pioglitazone or glimepiride
T15	i 796 805	PERISCOPE
T16	i 808 820	Pioglitazone
T17	i 1568 1580	pioglitazone
T18	i 1661 1675	apolipoprotein
T19	i 1709 1723	apolipoprotein
T20	i 1758 1769	glimepiride
T21	i 2356 2368	pioglitazone
T22	o 19 74	triglyceride/high-density lipoprotein cholesterol ratio
T23	o 135 158	progression of coronary
T24	o 559 581	atheroma progression .
T25	o 595 613	slowed progression
T26	o 934 954	atheroma progression
T27	o 1042 1064	biochemical parameters
T28	o 1067 1118	percent atheroma volume , and total atheroma volume
T29	o 1207 1337	in high-density lipoprotein cholesterol ( HDL-C ) and reductions in glycated hemoglobin , triglycerides , and C-reactive protein .
T30	o 1396 1437	percent atheroma volume and triglycerides
T31	o 1464 1488	triglyceride/HDL-C ratio
T32	o 1515 1540	and glycated hemoglobin (
T33	o 1587 1633	changes in low-density lipoprotein cholesterol
T34	o 1661 1677	apolipoprotein B
T35	o 1709 1727	apolipoprotein A-I
T36	o 1784 1803	atheroma regression
T37	o 1818 1829	progression
T38	o 1869 1887	increases in HDL-C
T39	o 1944 1957	triglycerides
T40	o 1995 2019	triglyceride/HDL-C ratio
T41	o 2058 2089	decrease in glycated hemoglobin
T42	o 2194 2212	triglyceride/HDL-C
T43	o 2245 2268	percent atheroma volume
T44	o 2286 2307	total atheroma volume
T45	o 2376 2400	triglyceride/HDL-C ratio
T46	o 2425 2445	atheroma progression